Viewing entries tagged
Boehringer Ingelheim

Xarelto Debuts as Top Ad Target

Xarelto Debuts as Top Ad Target

Opening a new front in the mass tort litigation wars, plaintiffs’ attorneys launched an aggressive advertising campaign targeting the blood thinner drug Xarelto in July -- increasing their total monthly ad spending by nearly $1.2 million to air over 1,800 ads. The advertising blitz follows reports from earlier this summer that the blood thinner, sold by Johnson & Johnson in the United States and Bayer in Europe, was facing its first lawsuits in the US. Read full article.